Breaking News, Financial News

AstraZeneca

AZ posted flat revenues, but a boost in earnings in 2Q09

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AstraZeneca 2Q09 2Q Revenues: $8.0 billion (flat) 2Q Earnings: $2.4 billion (+70%) YTD Revenues: $15.7 billion (flat) YTD Earnings: $4.0 billion (+21%) Comments: Two generic marketers of Toprol-XL withdrew from the U.S. market,and the introduction of generic Casodex was delayed, giving AZ a boost. Nexium posted a 6% drop in sales in 2Q09 to $1.2 billion, while Crestor posted a 23% rise to $1.1 billion. Nexium sales rose 12% to $1.2 billion. Seloken/Toprol-XL sales doubled to $417 ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters